Higher Responder Rates Observed With Live Participant Assessment Versus Photo Assessment After VYC-20L Hyaluronic Acid Treatment for Chin Augmentation

In an evaluator-blinded, randomized controlled trial, the hyaluronic acid soft-tissue filler VYC-20L injectable gel (Juvéderm® Voluma™ XC, Allergan Aesthetics, an AbbVie Company) was safe and effective for correcting volume deficits and retrusion in the chin.The objective of this subanalysis is to compare responder rates obtained with photo versus live assessments.Participants were randomized 3:1 to VYC-20L treatment or a 6-month, no-treatment control period followed by optional treatment. Responder rates (≥1-point improvement from baseline on the validated Allergan Chin Retrusion Scale [ACRS]) obtained with photo assessments and live assessments at month 6 were compared. Prespecified subgroup analyses compared responder rates by baseline ACRS severity, filler volume, cannula usage, and investigational site.VYC-20L was effective for chin augmentation as evaluated with both live and photo assessments. The ACRS responder rates at month 6 were 91.8% with live assessments and 56.3% with photo assessments. Consistently higher response rates were observed by live versus photo assessment regardless of baseline ACRS severity, filler volume, cannula usage, and investigational site.Live assessment of ACRS response after VYC-20L treatment resulted in higher responder rates than photo assessment, thus supporting the use of live assessment for this indication to approximate real-world clinical practice.